東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Drug Repurposing of an EGFR Inhibito...

Dabestani, Parinaz Jila.

FindBook

Google Book

Amazon

博客來

Drug Repurposing of an EGFR Inhibitor for Protection against Noise-Induced Hearing Loss.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Drug Repurposing of an EGFR Inhibitor for Protection against Noise-Induced Hearing Loss./
作者:	Dabestani, Parinaz Jila.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	85 p.
附註:	Source: Masters Abstracts International, Volume: 82-01.
Contained By:	Masters Abstracts International82-01.
標題:	Medicine. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28001904
ISBN:	9798641733333

Drug Repurposing of an EGFR Inhibitor for Protection against Noise-Induced Hearing Loss.
Dabestani, Parinaz Jila.

Drug Repurposing of an EGFR Inhibitor for Protection against Noise-Induced Hearing Loss. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 85 p.

Source: Masters Abstracts International, Volume: 82-01.

Thesis (M.S.)--Creighton University, 2020.

This item must not be sold to any third party vendors.

Noise-induced Hearing Loss (NIHL) is a clinically significant phenomena that affects a variety of patient populations and negatively impacts quality of life. There is currently no drug approved by the Food and Drug Administration (FDA) for protection against NIHL. Repurposing an already approved FDA drug is the most cost effective and efficient. Using an in silico screen, we identified top drug hits for protective agents against NIHL. This was done via mouse model transcriptomes collected by Gratton et al., 2011, and available on the NCBI Gene Expression Omnibus (GEO) database. Afatinib was found to cover the most NIHL pathways through this method and was therefore chosen for our study. Afatinib is an FDA approved inhibitor of the epidermal growth factor receptor (EGFR) family for use against non-small cell lung carcinoma (NSCLC). A noise exposure paradigm of 100 dB for 2 hours (8-16kHz) was employed, followed by functional cochlear testing. Afatinib showed protection against hearing loss in both auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) testing. Afatinib effects on ABR results showed sexual dimorphism with only significant results for females. DPOAE results showed significant results for both males and females combined. This suggests that our in silico screen was effective and afatinib is protective against noise-induced hearing loss. Future studies include exploring the mechanism of afatinib's protective properties, exploration of the sexually dimorphic effects of afatinib, and translation to clinical studies.

ISBN: 9798641733333Subjects--Topical Terms:

641104
Medicine.
Subjects--Index Terms:

Afatinib

Drug Repurposing of an EGFR Inhibitor for Protection against Noise-Induced Hearing Loss.
LDR:02668nmm a2200349 4500 001 2284564
005 20211123073347.5
008 220723s2020 ||||||||||||||||| ||eng d
020 $a 9798641733333
035 $a (MiAaPQ)AAI28001904
035 $a AAI28001904
040 $a MiAaPQ $c MiAaPQ
100 1 $a Dabestani, Parinaz Jila. $3 3563740
245 1 0 $a Drug Repurposing of an EGFR Inhibitor for Protection against Noise-Induced Hearing Loss.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 85 p.
500 $a Source: Masters Abstracts International, Volume: 82-01.
500 $a Advisor: Zuo, Jian.
502 $a Thesis (M.S.)--Creighton University, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Noise-induced Hearing Loss (NIHL) is a clinically significant phenomena that affects a variety of patient populations and negatively impacts quality of life. There is currently no drug approved by the Food and Drug Administration (FDA) for protection against NIHL. Repurposing an already approved FDA drug is the most cost effective and efficient. Using an in silico screen, we identified top drug hits for protective agents against NIHL. This was done via mouse model transcriptomes collected by Gratton et al., 2011, and available on the NCBI Gene Expression Omnibus (GEO) database. Afatinib was found to cover the most NIHL pathways through this method and was therefore chosen for our study. Afatinib is an FDA approved inhibitor of the epidermal growth factor receptor (EGFR) family for use against non-small cell lung carcinoma (NSCLC). A noise exposure paradigm of 100 dB for 2 hours (8-16kHz) was employed, followed by functional cochlear testing. Afatinib showed protection against hearing loss in both auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) testing. Afatinib effects on ABR results showed sexual dimorphism with only significant results for females. DPOAE results showed significant results for both males and females combined. This suggests that our in silico screen was effective and afatinib is protective against noise-induced hearing loss. Future studies include exploring the mechanism of afatinib's protective properties, exploration of the sexually dimorphic effects of afatinib, and translation to clinical studies.
590 $a School code: 0339.
650 4 $a Medicine. $3 641104
650 4 $a Audiology. $3 537237
653 $a Afatinib
653 $a Drug repurposing
653 $a EGFR inhibitor
653 $a Noise-induced hearing loss
690 $a 0564
690 $a 0300
710 2 $a Creighton University. $b Biomedical Science. $3 3563741
773 0 $t Masters Abstracts International $g 82-01.
790 $a 0339
791 $a M.S.
792 $a 2020
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28001904